Skip to content

    Syngene Intl.

    SYNGENEGood
    Healthcare·23 Jan 2025
    Management Summary

    Syngene reported a strong recovery in Q3 FY25 with 11% revenue growth and significant margin expansion, driven by a return to growth in Discovery Services and continued traction in Biologics. While the US biotech funding environment is stabilizing, the recovery is taking 8-12 weeks longer than management initially anticipated, leading to a moderated full-year revenue outlook. The company is successfully converting 'China Plus One' pilot projects into long-term contracts and expects its newly acquired Unit-III facility to be operational by April 2025.

    Highlights

    7

    • Reported revenue from operations of ₹944 crores, up 11% YoY, marking a return to growth after two quarters of decline.

    • Operating EBITDA increased 23% YoY to ₹284 crores, with margins expanding 300 bps to 30.1%.

    • Constant currency revenue growth stood at 8%, aided by a 3% favorable foreign exchange benefit.

    • Reported PAT after exceptional items grew 18% YoY to ₹131 crores.

    • Revenue mix shifted to 60% Research (Discovery Services) and 40% Development & Manufacturing (CDMO).

    • Full-year revenue guidance revised downwards to 'single-digit growth' due to an 8-12 week delay in market recovery.

    • Net cash position remains strong at ₹838 crores as of December 2024 after meeting CAPEX requirements.

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue from Operations₹944 Cr+11%YoY
    2. 02Operating EBITDA₹284 Cr+23%YoY
    3. 03Operating EBITDA Margin30.1%
    4. 04PAT (after exceptional items)₹131 Cr+18%YoY
    5. 05Net Cash₹838 Cr

    Segment breakdown

    Discovery Services (Research)
    60% Revenue Share0 growth Performance
    Development and Manufacturing (CDMO)
    40% Revenue Share0 Biologics Key Driver
    List

    Guidance & targets

    4
    CategoryTargetPriority
    Revenue
    Full Year Revenue Growth
    single digit
    		Medium
    Margin
    Full Year Operating EBITDA Margin
    high 20s
    		High
    Capex
    Annual CAPEX
    60 million
    		High
    Capacity
    Unit-III Facility Readiness
    April
    		High

    Risks & concerns

    5
    RiskSeverity

    Delayed Biotech Funding Recovery

    Recovery in US biotech funding is 8-12 weeks behind the initial internal forecast, impacting full-year revenue targets. — Management acknowledged

    medium

    Increased Effective Tax Rate

    Tax rate rose to 22.2% from 19.3% as facilities move out of favorable SEZ tax status. — Management acknowledged

    low

    Underutilization of New Facilities

    Analysts questioned the drag on profitability from underutilized sites like Mangalore and the newly acquired Unit-III. — Analyst downplayed

    medium

    Areas of Evasion(2)

    • Specific cost drag of underutilized facilities
    • Individual client contract updates (Baxter, Zoetis)

    Q&A highlights

    3

    “the rate of stabilization in the biotech funding took longer in the year than what we'd included in our original guidance... just phase shifted out by those eight to 12 weeks.”

    Explains the downward revision in full-year guidance as a timing issue rather than a loss of market share.

    asked by Shyam Srinivasan, Goldman Sachs

    2 min read5 chapters

    Detailed Narrative

    01

    Return to Growth and Margin Expansion

    Syngene achieved a significant milestone in Q3 FY25 by returning to YoY revenue growth of 11% (₹944 crores) after two consecutive quarters of decline. This recovery was accompanied by a robust 300 bps expansion in Operating EBITDA margins to 30.1%. The margin improvement was primarily driven by lower material costs, which fell to 25.2% of revenue from 27.8% in the previous year, alongside efficiency gains and a favorable business mix.

    02

    US Biotech Funding and Guidance Revision

    Management noted signs of stabilization in the US biotech funding environment during the quarter. However, the recovery has been delayed by approximately 8 to 12 weeks compared to the assumptions made at the start of the fiscal year. Consequently, Syngene revised its full-year revenue guidance to 'single-digit growth,' down from the previous expectation of high single-digit to low double-digit growth, while maintaining its margin guidance in the high 20s.

    03

    Strategic Conversion of 'China Plus One' Pilots

    A key strategic highlight was the conversion of initial pilot projects with mid and large pharma companies into longer-term contracts. These projects are part of a broader structural trend where biopharma companies are rebalancing supply chains away from China. Management emphasized that this 'tectonic' shift is a multi-year tailwind for the Indian industry, rather than a short-term reaction to specific legislation like the Biosecure Act.

    04

    Capacity Expansion and Unit-III Readiness

    The company continues to invest in long-term capacity, with 9M FY25 CAPEX reaching $34 million out of a full-year target of $60 million. The newly acquired Unit-III facility (formerly Stelis) is undergoing retooling and is on track to be ready for client work by April 2025. This facility is critical for addressing the capacity headroom needed for future growth in the Biologics segment, which is currently seeing strong traction.

    05

    Segment Mix and Commercial Footprint

    Syngene's revenue split is currently 60% Research (Discovery Services) and 40% Development and Manufacturing (CDMO). To capture global demand, the company has increased its commercial headcount by 14%, placing more sales staff in Western markets close to clients. While this increases the salary bill, management views it as a necessary investment to build closer relationships and secure high-value contracts in a competitive global landscape.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.